<DOC>
	<DOCNO>NCT02252796</DOCNO>
	<brief_summary>This study help researcher test safety hypofractionated dose radiotherapy ( HySBst ) different dose level chemo-radiation Non Small Cell Lung Cancer .</brief_summary>
	<brief_title>Phase I Hypofractionated Stereotactic Boost ( Radiotherapy ) Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Patients assign Sub-group 1 2 base primary lesion size location . This protocol utilize standard 3 + 3 phase I design three patient enrol per cohort . Patients offer opportunity participate blood specimen component study . Patients follow 2 year post radiation therapy . Sub-group 1 receive HySBst 1 week . Weeks 2-7 standard chemo-radiation therapy . Patients option consolidative chemotherapy week 12 . Sub-group 2 receive standard chemo-radiation therapy week 1-6 receive HySBst week 7 . Patients option consolidative chemotherapy week 12 . HySBst dose escalation sub-group list : Optional : 4 Gy x 4 daily fraction Level 1 : 5 Gy x 4 daily fraction Level 2 : 5.5 Gy x 4 daily fraction Level 3 : 6 Gy x 4 daily fraction DLTs base event occur course HySBst . Chemo-Radiation Therapy define : Standard Carboplatin &amp; Paclitaxel Doublelet Regimen weekly Carboplatin AUC 2/week Paclitaxel 45 mg/ m2/ week conventionally fractionate IMRT Image-guided IMRT 60 Gy , 5 x per week 6 week Consolidative chemotherapy define Carboplatin AUC 6 Paclitaxel 200 mg/m2 every 21 day x 2 cycle give ALL radiotherapy deliver .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Stage II III Non Small Cell Lung Cancer Primary tumor directly invade mediastinal structure , heart , major blood vessel , esophagus , trachea , proximal bronchial tree . Prior chemotherapy NSCLC Prior radiotherapy region study cancer would result overlap radiation therapy field . Severe , active comorbidity Pregnancy woman childbearing potential Any history allergic reaction paclitaxel taxanes , carboplatin Uncontrolled neuropathy â‰¥ grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>Radiotherapy Therapy</keyword>
</DOC>